肺がん[業績]

• 2023年度

  1. Ogimoto T, Ozasa H, Tsuji T, Funazo T, Yamazoe M, Hashimoto K, Yoshida H,
     Hosoya K, Ajimizu H, Nomizo T, Yoshida H, Hamaji M, Menju T, Yoshizawa A, Date H, Hirai T.Combination therapy with EGFR tyrosine kinase inhibitors and TEAD inhibitor increases tumor suppression effects in EGFR mutation-positive lung cancer. Mol Cancer Ther. 2023 Dec 6. doi: 10.1158/1535-7163.MCT-23-0371.
  2. Ogimoto T, Ozasa H, Yoshida H, Nomizo T, Funazo T, Yoshida H, Hashimoto K, Hosoya K, Yamazoe M, Ajimizu H, Tsuji T, Sakamori Y, Kuninaga K, Morita S, Hirai T. CD47 polymorphism for predicting nivolumab benefit in patients with advanced non‑small‑cell lung cancer. Oncol Lett. 26(2):364. (2023)
  3. Yamazoe M, Ozasa H, Tsuji T, Funazo T, Yoshida H, Hashimoto K, Hosoya K, Ogimoto T, Ajimizu H, Yoshida H, Itotani R, Sakamori Y, Kuninaga K, Aoki W, Hirai T. Yes-associated protein 1 mediates initial cell survival during lorlatinib treatment through AKT signaling in ROS1-rearranged lung cancer. Cancer Sci. 114(2):546-560. (2023)
  4. Katayama Y, Yamada T, Tanimura K, Tokuda S, Morimoto K, Hirai S, Matsui Y, Nakamura R, Ishida M, Kawachi H, Yoneda K, Hosoya K, Tsuji T, Ozasa H, Yoshimura A, Iwasaku M, Kim YH, Horinaka M, Sakai T, Utsumi T, Shiotsu S, Takeda T, Katayama R, Takayama K. Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer. NPJ Precis Oncol. 7(1):12. (2023)
  5. Kishi N, Matsuo Y, Shintani T, Ogura M, Mitsuyoshi T, Araki N, Fujii K, Okumura S, Nakamatsu K, Kishi T, Atsuta T, Sakamoto T, Ohtsu S, Katagiri T, Narabayashi M, Fujishiro S, Iizuka Y, Ozasa H, Hirai T, Mizowaki T; Kyoto Radiation Oncology Study Group (KROSG). Recurrence patterns and progression-free survival after chemoradiotherapy with or without consolidation durvalumab for stage III non-small cell lung cancer. J Radiat Res.64(1):142-153. (2023)
  6. Yuasa I, Hamaji M, Ozasa H, Sakamori Y, Yoshida H, Yutaka Y, Menju T, Hirai T, Date H.
     Outcomes of immune checkpoint inhibitors for postoperative recurrence of non-small cell lung cancer.Y Gen Thorac Cardiovasc Surg. 71(9):534-541.(2023)

  2022年度

  1. Tanaka K, Chamoto K, Saeki S, Hatae R, Ikematsu Y, Sakai K, Ando N, Sonomura K, Kojima S, Taketsuna M, Kim YH, Yoshida H, Ozasa H, Sakamori Y, Hirano T, Matsuda F, Hirai T, Nishio K, Sakagami T, Fukushima M, Nakanishi Y, Honjo T, Okamoto I : Combination bezafibrate and nivolumab treatment of patients with advanced non-small cell lung cancer. Sci Transl Med. 2022; 14 (675).
  2. Yamazoe M, Ozasa H, Tsuji T, Funazo T, Yoshida H, Hashimoto K, Hosoya K, Ogimoto T, Ajimizu H, Yoshida H, Itotani R, Sakamori Y, Kuninaga K, Aoki W, Hirai T: Yes-associated protein 1 mediates initial cell survival during lorlatinib treatment through AKT signaling in ROS1-rearranged lung cancer. Cancer Sci. 2023; 114 (2):546-560.
  3. Hashimoto K, Ozasa H, Yoshizawa A, Yoshida H, Ogimoto T, Hosoya K, Yamazoe M, Ajimizu H, Funazo T, Yoshida H, Sakamori Y, Hirai T:Sarcomatoid malignant pleural mesothelioma treated with nivolumab: A case series.Oncol Lett. 2022 Sep 22;24(5):402.
  4. Kishi N, Matsuo Y, Shintani T, Ogura M, Mitsuyoshi T, Araki N, Fujii K, Okumura S, Nakamatsu K, Kishi T, Atsuta T, Sakamoto T, Ohtsu S, Katagiri T, Narabayashi M, Fujishiro S, Iizuka Y, Ozasa H, Hirai T, Mizowaki T; Kyoto Radiation Oncology Study Group (KROSG):Recurrence patterns and progression-free survival after chemoradiotherapy with or without consolidation durvalumab for stage III non-small cell lung cancer.J Radiat Res. 2023 Jan 20;64(1):142-153.
  5. Ueki K, Matsuo Y, Kishi N, Yoneyama M, Yoshida H, Sakamori Y, Ozasa H, Hirai T, Mizowaki T : Usefulness of pro-gastrin-releasing peptide as a predictor of the incidence of brain metastasis and effect of prophylactic cranial irradiation in patients with limited-stage small-cell lung cancer. J Radiat Res. 2022 Jul 19;63(4):636-645.
  6. Nagata S, Hamaji M, Ozasa H, Yamada Y, Ohsumi A, Date H : Salvage Surgery After Immune Checkpoint Inhibitors for Advanced Non-Small Cell Lung Cancer: Potential Association Between Immune-Related Adverse Events and Longer Survival. Clin Lung Cancer. 2022 Jul;23(5):e321-e324.

  2021年度

  1. Ajimizu H, Ozasa H, Sato S, Funazo T, Sakamori Y, Nomizo T, Kuninaga K, Ogimoto T, Hosoya K, Yamazoe M, Tsuji T, Yoshida H, Itotani R, Ueno K, Kim YH, Muro S, Hirai T.
     “Survival impact of treatment for chronic obstructive pulmonary disease in patients with advanced non-small-cell lung cancer.”
Sci Rep. 2021 Dec 8;11(1):23677.
  2. Yoshida H, Nomizo T, Ozasa H, Tsuji T, Funazo T, Yasuda Y, Ajimizu H, Yamazoe M, Kuninaga K, Ogimoto T, Hosoya K, Itotani R, Sakamori Y, Kim YH, Hirai T. PD-L1 polymorphisms predict survival outcomes in advanced non-small-cell lung cancer patients treated with PD-1 blockade. Eur J Cancer 144. 317-325. 2021. 
  3. Yoshida H, Iwatsubo S, Nishimura T. PD-1 Inhibitor for a non-small-cell lung cancer patient with paraneoplastic nephropathy. Arch Bronconeumol 57(4). 311-312. 2021. 
  4. Sueoka-Aragane N, Nakashima C, Yoshida H, Matsumoto N, Iwanaga K, Ebi N, Nishiyama A, Yatera K, Kuyama S, Fukuda M, Ushijima S, Umeguchi H, Harada D, Kashiwabara K, Suetsugu T, Fujimoto N, Tanaka F, Uramoto H, Yoshii C, Nakatomi K, Koh G, Seki N, Aoe K, Nosaki K, Inoue K, Takamori A, Kawaguchi A.
      The role of comprehensive analysis with circulating tumor DNA in advanced non-small cell lung cancer patients considered for osimertinib treatment. Cancer Med 10(12). 3873-3885. 2021. 
  5. Yutaka Y, Yuasa I, Itotani R, Date H. 
     A novel guidewire technique for endobronchial silicone plug occlusion for bronchopleural fistula.
     Multimed Man Cardiothorac Surg 2021.
  6. Sakai T, Udagawa H, Kirita K, Nomura S, Itotani R, Tamiya Y, Sugimoto A, Ota T, Naito T, Izumi H, Nosaki K, Ikeda T, Zenke Y, Matsumoto S, Yoh K, Niho S, Nakai T, Ishii G, Goto K. 　　
     Comparison of the efficiency of endobronchial ultrasound-guided transbronchial needle aspiration using a 22G needle versus 25G needle for the diagnosis of lymph node metastasis in patients with lung cancer: a prospective randomized, crossover study.”
     Transl Lung Cancer Res 10(9): 3745-3758.
  7. Hosoya K, Fujimoto D, Morimoto T, Kumagai T, Tamiya A, Taniguchi Y, Yokoyama T, Ishida T, Matsumoto H, Hirano K, Kominami R, Tomii K, Suzuki H, Hirashima T, Tanaka S, Uchida J, Morita M, Kanazu M, Mori M, Nagata K, Fukuda I and Tamiya M: 
     Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter study. 
     BMC Cancer  21(1). 346. 2021

  2020年度

  1. Takahiro Tsuji, Hiroaki Wake, Mariko Shindo, Koichiro Haruwaka, Hitomi Ajimizu, Masatoshi Yamazoe, Tomoko Funazo, Yuto Yasuda, Hironori Yoshida, Yuichi Sakamori, Young Hak Kim, Hiroaki Ozasa and Toyohiro Hirai: Novel in vivo imaging method to evaluate “Don’t eat me” signal of tumor against microglia. AACR annual meeting 2020. 2020.4.27. San Diego (online)
  2. Keisuke Kirita, Hibiki Udagawa, Ryo Itotani, Yutaro Tamiya, Kaname Nosaki, Yoshitaka Zenke, Takaya Ikeda, Shingo Matsumoto, Kiyotaka Yoh, Seiji Niho and Koichi Goto：Clinical Utility of Endobronchial-Ultrasound Guided Miniforceps Biopsy for Hilar and Mediastinal lymph nodes. 21st the World Congress of Bronchology and Interventional Pulmonology and The 8th National Interventional Pulmonology Congress of the Chinese Medical Association. 2020.11.9-11.22 Shanghai.

  2019年

  1. Tsuji T,Ozasa H,Aoki W,Aburaya S,Funazo T,Furugaki K,Yoshimura Y,Ajimizu H,Okutani R,Yasuda Y,Nomizo T,Uemasu K,Hasegawa K,Yoshida H,Yagi Y,Nagai H,Sakamori Y,Ueda M,Hirai T,Kim YH:Alectinib Resistance in ALK-Rearranged Lung Cancer by Dual Salvage Signaling in a Clinically Paired Resistance Model. Mol Cancer Res 17(1). 212-224. 2019.
  2. Tsuji T,Ozasa H,Aoki W,Aburaya S,Yamamoto Funazo T,Furugaki K,Yoshimura Y,Yamazoe M,Ajimizu H,Yasuda Y,Nomizo T,Yoshida H,Sakamori Y,Wake H,Ueda M,Kim YH,Hirai T:YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation. Nat Commun (in press)
  3. Funazo TY,Nomizo T,Ozasa H,Tsuji T,Yasuda Y, Yoshida H,Sakamori Y,Nagai H,Hirai T, Kim YH:Clinical impact of low serum free T4 in patients with non-small cell lung cancer treated with nivolumab. Sci Rep 19(9). 17085. 2019.
  4. Yamazoe M,Ozasa H,Kim YH:Effectiveness of Nivolumab on Sarcomatoid Malignant Pleural Mesothelioma With Eosinophilia and Eosinophilic Pleural Effusion.　J Thorac Oncol 14(11). e251-e253. 2019.
  5. Fujita K,Kim YH,Kanai O,Yoshida H,Mio T,Hirai T:Emerging concerns of infectious diseases in lung cancer patients receiving immune checkpoint inhibitor therapy. Respir Med 146. 66-70. 2019.
  6. Yokoyama T,Yoshioka H,Fujimoto D,Demura Y,Hirano K,Kawai T,Kagami R,Washio Y,Ishida T,Kogo M,Tomii K,Okuno T,Akai M,Hirabayashi M,Nishimura T,Nakahara Y, Kim YH,Miyakoshi C,Yoshimura K,Hirai T:Kyoto Thoracic Oncology Research Group (KTORG). A phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402). Lung Cancer 135. 175-180. 2019.
  7. Fujimoto D,Yoshioka H,Kataoka Y,Morimoto T,Hata T,Kim YH,Tomii K,Ishida T,Hirabayashi M,Hara S,Ishitoko M,Fukuda Y,Hwang MH,Sakai N,Fukui M,Nakaji H,Morita M,Mio T,Yasuda T,Sugita T,Hirai T:Pseudoprogression in Previously Treated Patients with Non-Small Cell Lung Cancer Who Received Nivolumab Monotherapy. J Thorac Oncol 14(3). 468-474. 2019.
  8. Eso Y,Kou T,Nagai H, Kim YH,Kanai M,Matsumoto S,Mishima-Iwai M,Arasawa S,Iguchi E,Nakamura F,Takeda H,Takai A,Takahashi K,Ueda Y,Muto M,Seno H:Utility of ultrasound-guided liver tumor biopsy for next generation sequencing-based clinical sequencing. Hepatol Res 49(5). 579-589. 2019.
  9. Yamauchi I,Yasoda A,Matsumoto S,Sakamori Y, Kim YH,Nomura M,Otsuka A,Yamasaki T,Saito R,Kitamura M,Kitawaki T,Hishizawa M,Kawaguchi-Sakita N,Fujii T,Taura D,Sone M,Inagaki N:Incidence,features,and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab. PLoS One 14(5). e0216954. 2019.

  2018年

  1. Yoshida H, Ooi M, Kim YH: Successful treatment with osimertinib and chemotherapy in a non-small cell lung cancer patient with EGFR mutation and meningeal carcinomatosis. J Thorac Oncol 13(11). e219-e220. 2018.
  2. Yoshida H, Kim YH, Ozasa H, Sakamori Y, Tsuji T, Nomizo T, Yasuda Y, Yamamoto T, Ajimizu H, Hirai T: Efficacy of ceritinib after alectinib for ALK-positive non-small cell lung cancer. In Vivo 32(6). 1587-1590. 2018.
  3. Kanai O, Kim YH, Demura Y, Kanai M, Ito T, Fujita K, Yoshida H, Akai M, Mio T, Hirai T: Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease. Thorac Cancer 9(7). 847-855. 2018.
  4. Yoshida H, Kim YH, Ozasa H, Nagai H, Sakamori Y, Tsuji T, Nomizo T, Yasuda Y, Funazo T, Hirai T. Nivolumab in non-small cell lung cancer with EGFR mutation. Ann Oncol 29(3). 777-7778. 2018.
  5. Mitsuyoshi T, Matsuo Y, Itou H, Shintani T, Iizuka Y, Kim YH, Mizowaki T. Evaluation of a prognostic scoring system based on the systemic inflammatory and nutritional status of patients with locally advanced non-small-cell lung cancer treated with chemoradiotherapy. J Radiat Res 59(1). 50-57. 2018.
  6. Fujimoto D, Yoshioka H, Kataoka Y, Morimoto T, Kim YH, Tomii K, Ishida T, Hirabayashi M, Hara S, Ishitoko M, Fukuda Y, Hwang MH, Sakai N, Fukui M, Nakaji H, Morita M, Mio T, Yasuda T, Sugita T, Hirai T. Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study. Lung Cancer 119. 14-20. 2018.
  7. Hamaji M, Motoyama H, Menju T, Chen-Yoshikawa TF, Sonobe M, Kim YH, Date H. Thoracoscopic rebiopsy to detect the T790M mutation after postoperative recurrence. Interact Cardiovasc Thorac Surg 27(4). 606-608. 2018.
  8. Hosomi Y, Tanai C, Yoh K, Goto Y, Sakai H, Kato T, Kaburagi T, Nishio M, Kim YH, Inoue A, Hasegawa Y, Isobe H, Tomizawa Y, Mori Y, Minato K, Yamada K, Ohashi Y, Kunitoh H. Characteristics and outcomes of patients with EGFR-mutation positive non-small-cell lung cancer receiving gefitinib beyond radiological progression. Expert Opin Pharmacother 19(10). 1049-1056. 2018.
  9. Kanai O, Kim YH, Demura Y, Kanai M, Ito T, Fujita K, Yoshida H, Akai M, Mio T, Hirai T. Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease. Thorac Cancer 9(7). 847-855. 2018.
  10. Akamatsu H, Katakami N, Okamoto I, Kato T, Kim YH, Imamura F, Shinkai M, Hodge RA, Uchida H, Hida T. Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial. Cancer Sci 109(6). 1930-1938. 2018.
  11. Hida T, Seto T, Horinouchi H, Maemondo M, Takeda M, Hotta K, Hirai F, Kim YH, Matsumoto S, Ito M, Ayukawa K, Tokushige K, Yonemura M, Mitsudomi T, Nishio M. Phase II study of ceritinib in alectinib-pretreated patients with anaplastic lymphoma kinase-rearranged metastatic non-small-cell lung cancer in Japan: ASCEND-9. Cancer Sci 109(9). 2863-2872. 2018.
  12. Yasuda Y, Ozasa H, Kim YH. PD-L1 Expression in Small Cell Lung Cancer. J Thorac Oncol 13(3). e40-e41. 2018.

  2017年度

  1. Yoshida H, Kim YH, Ozasa H, Nagai H, Sakamori Y, Tsuji T, Nomizo T, Funazo T, Yasuda Y, Hirai T. EGFR T790M Detection in Circulating Tumor DNA from Non-small Cell Lung Cancer Patients Using the PNA-LNA Clamp Method. Anticancer Res. 2017 May;37(5):2721-2725.
  2. Yoshida H, Kim YH. Successful Osimertinib Rechallenge after Severe Osimertinib-Induced Hepatotoxicity. J Thorac Oncol. 2017 May;12(5):e61-e63.
  3. Hida T, Nokihara H, Kondo M, Kim YH, Azuma K, Seto T, Takiguchi Y, Nishio M, Yoshioka H, Imamura F, Hotta K, Watanabe S, Goto K, Satouchi M, Kozuki T, Shukuya T, Nakagawa K, Mitsudomi T, Yamamoto N, Asakawa T, Asabe R, Tanaka T, Tamura T. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. Lancet. 2017 May 10. pii: S0140-6736(17)30565-2.
  4. Takahiro Tsuji, Yuichi Sakamori, Hiroaki Ozasa, Yoshitaka Yagi, Hitomi Ajimizu, Yuto Yasuda, Tomoko Funazo, Takashi Nomizo, Hironori Yoshida, Hiroki Nagai, Ken Maeno, Tetsuya Oguri, Toyohiro Hirai1 and Young Hak Kim. Clinical impact of high serum hepatocyte growth factor in advanced non-small cell lung cancer. Oncotarget May 16, 2017 doi: 10.18632/oncotarget.17895
  5. Yuto Yasuda, Takashi Nomizo, Hiroaki Ozasa, Tomoko Funazo, Takahiro Tsuji, Hironori Yoshida, Yuichi Sakamori, Hiroki Nagai, Tomohiro Handa, Takeshi Kubo, Young Hak Kim A retrospective analysis of acute exacerbation of interstitial lung diseases with nanoparticle albumin-bound paclitaxel in patients with advanced lung cancer with preexisting interstitial lung disease Mol Clin Oncol. 2017 In press
  6. Tomoko Funazo, Takashi Nomizo, Young Hak Kim, Liver metastasis is associated with poor progression-free survival in patients with non-small cell lung cancer treated with nivolumab. J Thorac Oncol; 2017 in press.
  7. Nobukazu Agatsuma, Yuto Yasuda, Hiroaki Ozasa. Malignant pleural mesothelioma harboring both G719C and S768I mutations of EGFR successfully treated with afatinib. J Thorac Oncol; 2017 in press.
  8. Yuto Yasuda, Yasuyo Nishikawa, Yuichi Sakamori, Makoto Terao, Kentaro Hashimoto, Tomoko Funazo, Takashi Nomizo, Takahiro Tsuji, Hironori Yoshida, Hiroki Nagai, Hiroaki Ozasa, Toyohiro Hirai, Young Hak Kim. Successful oral desensitization with crizotinib after crizotinib-induced hepatitis in an anaplastic lymphoma kinase rearranged non-small cell lung cancer patient. Mol Clin Oncol; 2017 in press.

  2016年度

  1. Yoshida H, Kim YH, Ozasa H, Nagai H, Sakamori Y, Nakaoku T, Yagi Y, Tsuji T, Nomizo T, Mishima M.Albumin-bound paclitaxel for the treatment of refractory or relapsed small-cell lung cancer. Mol Clin Oncol. 2016 Jul;5(1):213-215.
  2. Shima H, Ozasa H, Tsuji T, Ajimizu H, Nomizo T, Yagi Y, Sakamori Y, Nagai H, Minamiguchi S, Kim YH, Mishima M. Response to chemotherapy with carboplatin plus albumin-bound paclitaxel in a patient with lymphoepithelioma-like thymic carcinoma: A case report. Mol Clin Oncol. 2016 May;4(5):715-718.
  3. Kim YH. Dual inhibition of BRAF and MEK in BRAF-mutated metastatic non-small cell lung cancer. J Thorac Dis. 2016 Sep;8(9):2369-2371.
  4. Kim YH. Prophylactic Cranial Irradiation for Extensive-Stage Small Cell Lung Cancer. J Thorac Oncol. 2016 Dec;11(12):e151-e152.
  5. Fujita K, Kim YH, Yoshizawa A, Mio T, Mishima M. Concomitant T790M mutation and small-cell lung cancer transformation after acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor. Respirology Case Reports. 2016 Dec 1;5(1): e00206
  6. Kobayashi Y, Azuma K, Nagai H, Kim YH, Togashi Y, Sesumi Y, Chiba M, Shimoji M, Sato K, Tomizawa K, Takemoto T, Nishio K, Mitsudomi T.Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer. Mol Cancer Ther. 2017 Feb;16(2):357-364.
  7. Nagai H, Kim YH. Cancer prevention from the perspective of global cancer burden patterns. J Thorac Dis. 2017 Mar;9(3):448-451.
  8. Takashi Nomizo, Hiroaki Ozasa, Takahiro Tsuji, Tomoko Funazo, Yuto Yasuda, Hironori Yoshida, Yoshitaka Yagi, Yuichi Sakamori, Hiroki Nagai, Toyohiro Hirai, Young Hak Kim. Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients Scientific Reports 2017 Mar 23;7:45124

  2015年度

  1. Tsuji T, Kim YH, Ozasa H: Successful treatment with carboplatin and nanoparticle albumin-bound paclitaxel in a patient with pulmonary spindle cell carcinoma. Respiratory Medicine Case Reports 15. 48-50. 2015.
  2. Shima H, Ozasa H, Tsuji T: Response to chemotherapy with carboplatin plus albumin‑bound paclitaxel in a patient with lymphoepithelioma‑like thymic carcinoma: A case report. Molecular and Clinical Oncology. 2015 (in press)
  3. Kunii E, Ozasa H, Oguri T: Reversal of c-MET-mediated Resistance to Cytotoxic Anticancer Drugs by a Novel c-MET Inhibitor TAS-115. Anticancer Res 35(10). 5241-5247. 2015.
  4. Kunii E, Oguri T, Kasai D, Ozasa H: Organic cation transporter OCT6 mediates cisplatin uptake and resistance to cisplatin in lung cancer. Cancer Chemother Pharmacol 75(5). 985-991. 2015.
  5. Kohno T, Nakaoku T, Tsuta K: Beyond ALK – RET, ROS1 and other oncogene fusions in lung cancer. Translational Lung Cancer Research 4(2). 156-164. 2015.
  6. Sakamori Y, Kim YH, Yoshida H: Effect of liver toxicity on clinical outcome of patients with non-small-cell lung cancer treated with pemetrexed. Mol Clin Oncol 3(2). 334-340. 2015.
  7. Tokuda S, Kim YH, Matsumoto H: Effects of Hydrostatic Pressure on Carcinogenic Properties of Epithelia. PLoS One 10(12). 2015.
  8. Ajimizu H, Kim YH, Mishima M: Rapid response of brain metastases to alectinib in a patient with non-small-cell lung cancer resistant to crizotinib. Med Oncol 32(2). 477. 2015.
  9. Kim YH, Mishima M: Relevance of platinum sensitivity in patients with relapsed or refractory small-cell lung cancer. J Thorac Oncol 10(5). e35. 2015.
  10. Kim YH, Mishima M: Maintenance Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor after First-Line Chemotherapy in Mutation-Positive Non-Small-Cell Lung Cancer. J Thorac Oncol 10(8). e81-82. 2015.
  11. Kim YH, Mishima M: Bevacizumab in Combination with Chemotherapy or Molecularly Targeted Agents for Non-Small-Cell Lung Cancer with Brain Metastases. J Thorac Oncol 10(8). e76. 2015.
  12. Fujita K, Kim YH, Nakatani K: Rapidly progressive sarcomatoid malignant mesothelioma of the pleura mimicking pulmonary empyema. Clinical Case Reports 3(10). 875-878. 2015.
  13. Shinke H, Masuda S, Togashi Y: Urinary kidney injury molecule-1 and monocyte chemotactic protein-1 are noninvasive biomarkers of cisplatin-induced nephrotoxicity in lung cancer patients. Cancer Chemother Pharmacol 76(5). 989-996. 2015.
  14. Kim YH, Mishima M. Consolidation Chemotherapy After Concurrent Chemoradiotherapy in Patients With Stage III Non-Small-Cell Lung Cancer. J Clin Oncol. 2016 Mar 1;34(7):767.
  15. Nobashi T, Koyasu S, Nakamoto Y, Kubo T, Ishimori T, Kim YH, Yoshizawa A, Togashi K. Prognostic value of fluorine-18 fludeoxyglucose positron emission tomography parameters differs according to primary tumour location in small-cell lung cancer. Br J Radiol. 2016 Mar;89(1059):20150618. doi: 10.1259/bjr.20150618. Epub 2016 Jan 12.
  16. Quality of life and survival survey of cancer cachexia in advanced non-small cell lung cancer patients-Japan nutrition and QOL survey in patients with advanced non-small cell lung cancer study. Takayama K, Atagi S, Imamura F, Tanaka H, Minato K, Harada T, Katakami N, Yokoyama T, Yoshimori K, Takiguchi Y, Hataji O, Takeda Y, Aoe K, Kim YH, Yokota S, Tabeta H, Tomii K, Ohashi Y, Eguchi K, Watanabe K. Support Care Cancer. 2016 Mar 22.

  2014年度

  1. Ozasa H, Oguri T, Maeno K, Takakuwa O, Kunii E, Yagi Y, Uemura T, Kasai D, Miyazaki M, Niimi A. Significance of c-MET Overexpression in Cytotoxic Anticancer Drug Resistant Small Cell Lung Cancer Cells. Cancer Sci. 2014 May 14
  2. Nakaoku T, Tsuta K, Ichikawa H, Shiraishi K, Sakamoto H, Enari M, Furuta K, Shimada Y, Ogiwara H, Watanabe S, Nokihara H, Yasuda K, Hiramoto M, Nammo T, Ishigame T, Schetter AJ, Okayama H, Harris CC, Kim YH, Mishima M, Yokota J, Yoshida T, Kohno T. Druggable oncogene fusions in invasive mucinous lung adenocarcinoma. Clin Cancer Res. 2014 Jun 15;20(12):3087-93.
  3. Kim YH, Nishimura T, Ozasa H, Nagai H, Sakamori Y, Iwata T, Sunadome H, Nishimura T, Mishima M. Phase II Study of Pemetrexed and Erlotinib in Pretreated Nonsquamous, Non-Small-Cell Lung Cancer Patients without an EGFR mutation. Chemotherapy. 2014 Jul 16;59(6):414-419.
  4. Tsuji T, Tanaka E, Yasuda I, Nakatsuka Y, Kaji Y, Yasuda T, Hashimoto S, Hwang M, Hajiro T, Taguchi Y. Nontuberculous mycobacteria in diffuse panbronchiolitis Respirology. 2015 Jan;20(1):80-6.
  5. Ajimizu H, Kim YH, Mishima M. Rapid response of brain metastases to alectinib in a patient with non-small-cell lung cancer resistant to crizotinib. Med Oncol. 2015 Feb;32(2):477.
  6. Sakamori Y, Kim YH, Yoshida H, Nakaoku T, Nagai H, Yagi Y, Ozasa H, Mishima M. Effect of liver toxicity on clinical outcome of patients with non-small-cell lung cancer treated with pemetrexed. Mol Clin Oncol. 2015 Mar;3(2):334-340.

  2013年度

  1. Kasai D, Ozasa H, Oguri T, Miyazaki M, Uemura T, Takakuwa O, Kunii E, Ohkubo H, Maeno K, Niimi A.Thymidylate synthase gene copy number as a predictive marker for response to pemetrexed treatment of lung adenocarcinoma.Anticancer Res. 2013 May;33(5):1935-40.
  2. Kim YH, Hirabayashi M, Kosaka S, Nikaidoh J, Yamamoto Y, Shimada M, Toyazaki T, Nagai H, Sakamori Y, Mishima M.　Phase II study of pemetrexed as first-line treatment in elderly (≥75) non-squamous non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0901.　Cancer Chemother Pharmacol. 2013 Jun;71(6):1445-51.
  3. Kim YH, Mishima M, Date H.　Combined” small cell and “pure” small cell lung cancer: is there a clinical difference?　Med Oncol. 2013 Jun;30(2):600.
  4. Fukudo M, Ikemi Y, Togashi Y, Masago K, Kim YH, Mio T, Terada T, Teramukai S, Mishima M, Inui KI, Katsura T.　Population Pharmacokinetics/Pharmacodynamics of Erlotinib and Pharmacogenomic Analysis of Plasma and Cerebrospinal Fluid Drug Concentrations in Japanese Patients with Non-Small Cell Lung Cancer. Clin Pharmacokinet. 2013 Jul;52(7):593-609.
  5. Kuriyama Y, Kim YH, Nagai H, Ozasa H, Sakamori Y, Mishima M.　Disease flare after discontinuation of crizotinib in anaplastic lymphoma kinase-positive　lung cancer.　Case Rep Oncol. 2013 Aug 14;6(2):430-3.
  6. Takakuwa O, Maeno K, Kunii E, Ozasa H, Hijikata H, Uemura T, Kasai D, Ohkubo H, Miyazaki M, Oguri T, Niimi A.Involvement of intermediate filament nestin in cell growth of small-cell lung cancer. Lung Cancer. 2013 Aug;81(2):174-9.
  7. Kim YH, Ozasa H, Nagai H, Sakamori Y, Yoshida H, Yagi Y, Nakaoku T, Mishima M. High-dose crizotinib for brain metastases refractory to standard-dose crizotinib. J Thorac Oncol. 2013 Sep;8(9):e85-6.
  8. Kim YH, Nagai H, Ozasa H, Sakamori Y, Mishima M. Therapeutic strategy for patients with non-small-cell lung cancer and brain metastases. Biomedical Reports. 2013 Sep;1(5):691-696.
  9. Nagai H, Kitano T, Nishimura T, Yasuda H, Nakata K, Takashima S, Kanai M, Matsumoto S, Mori Y, Kakudo Y, Sato H, Yamaguchi T, Kameno K, Kim YH, Mishima M, Yanagihara K. Use of glucose solution for the alleviation of gemcitabine-induced vascular pain: a double-blind randomized crossover study.　Support Care Cancer. 2013 Dec;21(12):3271-8.
  10. Yagi Y, Kim YH, Tajima N, Baba K, Aihara K, Soo HH, Yamaoka S, Mishima M. Long survival of a small-cell lung cancer patient who received maintenance chemotherapy with irinotecan. Case Rep Oncol. 2013 Nov 14;6(3):569-73.

  2012年度

  1. Masago K, Togashi Y, Fujita S, Nagai H, Sakamori Y, Okuda C, Kim YH, Mishima M.　Effect of the BCL2 Gene Polymorphism on Survival in Advanced-Stage Non-Small Cell Lung Cancer Patients Who Received Chemotherapy.　Oncology. 2013 Jan 24;84(4):214-218.
  2. Togashi Y, Masago K, Ito Y, Sakamori Y, Okuda C, Fukuhara A, Nagai H, Kim YH, Mishima M. Pneumocystis jiroveci pneumonia and colonization in patients with advanced lung cancer. Oncol Lett. 2013 Feb;5(2):601-604.
  3. Kim YH, Okuda C, Sakamori Y, Masago K, Togashi Y, Mishima M. Continuous morphine infusion for end-stage lung cancer patients. Oncol Lett. 2013 Mar;5(3):972-974.
  4. Togashi Y, Masago K, Handa T, Tanizawa K, Okuda C, Sakamori Y, Nagai H, Kim YH, Mishima M.　Prognostic Significance of Preexisting Interstitial Lung Disease in Japanese Patients with Small-Cell Lung Cancer.　Clin Lung Cancer. 2012 Jul;13(4):304-11.
  5. Kim YH, Sumiyoshi S, Hashimoto S, Masago K, Togashi Y, Sakamori Y, Okuda C, Mio T, Mishima M.　Expressions of Insulin-Like Growth Factor Receptor-1 and Insulin-Like Growth Factor Binding Protein 3 in Advanced Non-Small-Cell Lung Cancer.　Clin Lung Cancer. 2012 Sep;13(5):385-90.
  6. Sakamori Y, Masago K, Ohmori K, Togashi Y, Nagai H, Okuda C, Kim YH, Ichiyama S, Mishima M.　Increase in circulating endothelial progenitor cells predicts response in patients with advanced non-small cell lung cancer.　 Cancer Sci. 2012 Jun;103(6):1065-70.
  7. Togashi Y, Masago K, Kubo T, Fujimoto D, Sakamori Y, Nagai H, Kim YH, Togashi K, Mishima M.　Association between vascular-poor area of primary tumors and epidermal growth factor receptor gene status in advanced lung adenocarcinoma.　Med Oncol. 2012 Dec;29(5):3169-75.
  8. Nagai H, Yasuda H, Hatachi Y, Xue D, Sasaki T, Yamaya M, Sakamori Y, Togashi Y, Masago K, Ito I, Kim YH, Mio T, Mishima M.　Nitric oxide (NO) enhances pemetrexed cytotoxicity via NOcGMP signaling in lung adenocarcinoma cells in vitro and in vivo.　Int J Oncol. 2012 Jul;41(1):24-30.
  9. Togashi Y, Masago K, Hamatani Y, Sakamori Y, Nagai H, Kim YH, Mishima M.　Successful erlotinib rechallenge for leptomeningeal metastases of lung adenocarcinoma after erlotinib-induced interstitial lung disease: A case report and review of the literature.　Lung Cancer. 2012 Aug;77(2):464-8.
  10. Togashi Y, Masago K, Masuda S, Mizuno T, Fukudo M, Ikemi Y, Sakamori Y, Nagai H, Kim YH, Katsura T, Mishima M.　Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer.　Cancer Chemother Pharmacol. 2012 Sep;70(3):399-405.
  11. Kim YH, Hirabayashi M, Togashi Y, Hirano K, Tomii K, Masago K, Kaneda T,
      Yoshimatsu H, Otsuka K, Mio T, Tomioka H, Suzuki Y, Mishima M. Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902. Cancer Chemother Pharmacol. 2012 Aug;70(2):271-6.

  2011年度

  1. Kim YH, Mishima M. Second-line chemotherapy for small-Cell Lung Cancer (SCLC). Cancer Treat Rev. 37: 143-50, 2011
  2. Kim YH, Mio T, Masago K, Togashi Y, Sakamori Y, Okuda C, Mishima M. EGFR mutation: Significance as a stratification factor in the era of molecular-targeted therapy. Oncology Letters. 2: 383-7, 2011
  3. Masago K, Fujita S, Togashi Y, Kim YH, Hatachi Y, Fukuhara A, Nagai H, Sakamori Y, Mio T, Mishima M. Clinicopathologic factors affecting the progression-free survival of patients with advanced non-small-cell lung cancer after gefitinib therapy. Clin Lung Cancer. 12(1):56-61, 2011
  4. Okuda C, Kim YH, Takeuchi K, Togashi Y, Masago K, Sakamori Y, Mio T, Mishima M.Successful treatment with pemetrexed in a patient with mucinous　bronchioloalveolar carcinoma: long-term response duration with mild toxicity. J Thorac Oncol. 6(3):641-2, 2011
  5. Kim YH, Ishii G, Ochiai A.　Excision repair cross-complementing-1 for small cell lung cancer. J Thorac Oncol. 6(3):652, 2011
  6. Masago K, Fujita S, Kim YH, Hatachi Y, Fukuhara A, Irisa K, Nagai H, Sakamori Y, Togashi Y, Mio T, Mishima M. Phase I study of the combination of nedaplatin and gemcitabine in previously untreated advanced squamous cell lung cancer. Cancer Chemother Pharmacol. 67(2):325-30, 2011
  7. Masago K, Fujita S, Mio T, Togashi Y, Kim YH, Hatachi Y, Fukuhara A, Irisa K, Sakamori Y, Mishima M. Clinical significance of the ratio between the alpha 2 plasmin inhibitor-plasmin complex and the thrombin-antithrombin complex in advanced non-small cell lung cancer. Med Oncol. 28(1):351-6, 2011
  8. Togashi Y, Masago K, Kubo T, Sakamori Y, Kim YH, Hatachi Y, Fukuhara A, Mio T, Togashi K, Mishima M. Association of diffuse, random pulmonary metastases, including miliary metastases, with epidermal growth factor receptor mutations in lung adenocarcinoma. Cancer. 117(4):819-25, 2011
  9. Togashi Y, Kim YH, Masago K, Sakamori Y, Okuda C, Mio T, Mishima M.Long-term Survival in a Patient with Small-cell Lung Cancer Undergoing Hemodialysis Who Received Multiple Courses of Chemotherapy. Jpn J Clin Oncol. 41(4):582-5, 2011
  10. Togashi Y, Masago K, Fujita S, Kim YH, Sakamori Y, Hatachi Y, Fukuhara A, Nagai H, Mio T, Mishima M. Association of the transforming growth factor ß1 promoter polymorphism, C-509T, with smoking status and survival in advanced non-small cell lung cancer. Oncol Rep. 25(2):377-82, 2011
  11. Masago K, Fujita S, Togashi Y, Irisa K, Sakamori Y, Hatach Yi, Fukuhara A, Nagai H, Kim YH, Mio T, Mishima M. Association between Brain Natriuretic Peptide and the distant metastases of advanced Non-Small Cell Lung Cancer Patients. Oncology Letters. 2: 253-6, 2011
  12. Sakamori Y, Kim YH, Okuda C, Togashi Y, Kinose D, Masago K, Mio T, Uji A, Mishima M.　Two Cases of Cancer-associated Retinopathy Combined with Small-cell Lung Cancer. Jpn J Clin Oncol. 41(5):669-73, 2011
  13. Kim YH, Mishima M. Maintenance chemotherapy for non-small-cell lung cancer. Cancer Treat Rev. 2011 Nov;37(7):505-10.
  14. Togashi Y, Kim YH, Masago K, Tamai K, Sakamori Y, Mio T, Mishima M.Pulmonary embolism due to internal jugular vein thrombosis in a patient with non-small cell lung cancer receiving bevacizumab. Int J Clin Oncol. 2011 Aug;16(4):444-6.
  15. Togashi Y, Masago K, Fujita S, Hatachi Y, Fukuhara A, Nagai H, Sakamori Y, Kim YH, Mio T, Mishima M. Differences in Adverse Events between 250 mg Daily Gefitinib and 150 mg Daily Erlotinib in Japanese Patients with Non-small Cell Lung Cancer. Lung Cancer 2011 Oct;74(1):98-102.
  16. Tanaka S, Sakamori Y, Niimi M, Hazama M, Kim YH, Yanagihara K.　Design paper: A phase II study of Bevacizumab and Erlotinib in patients with non-Squamous non-small cell lung cancer that is refractory or relapsed after 1-2 previous Treatment (BEST).　Trials 2011 May 12;12:120.
  17. Togashi Y, Masago K, Fukudo M, Tsuchido Y, Okuda C, Kim YH, Ikemi Y, Sakamori Y, Mio T, Katsura T, Mishima M. Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation. Cancer Chemother Pharmacol. 2011 Oct;68(4):1089-92.
  18. Masago K, Togashi Y, Fukudo M, Terada T, Irisa K, Sakamori Y, Kim YH, Mio T, Inui KI, Mishima M.　Plasma and Pleural Fluid Pharmacokinetics of Erlotinib and its Active Metabolite OSI-420 in Patients with Non-Small-Cell Lung Cancer with Pleural Effusion.　Clin Lung Cancer. 2011 Sep;12(5):307-12.
  19. Masago K, Togashi Y, Fujita S, Sakamori Y, Okuda C, Kim YH, Mio T, Mishima M.　Clinical significance of serum hepatocyte growth factor and epidermal growth factor gene somatic mutations in patients with non-squamous non-small cell lung cancer receiving gefitinib or erlotinib.　Med Oncol. 2011 Jul 21.
  20. Masago K, Fujita S, Togashi Y, Kim YH, Hatachi Y, Fukuhara A, Nagai H, Irisa K, Sakamori Y, Mio T, Mishima M.　Clinical significance of epidermal growth factor receptor mutations and insulin-like growth factor 1 and its binding protein 3 in advanced non-squamous non-small cell lung cancer.　Oncol Rep. 2011 Oct;26(4):795-803.
  21. Kim YH, Mishima M.　How Should We Use Bevacizumab in Patients with Non-small Cell Lung Cancer?　J Thorac Oncol. 2011 Dec;6(12):2145-6.
  22. Kim YH, Fukuhara A, Mishima M.　Should Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Be Continued beyond Progressive Disease?　Case Rep Oncol. 2011 Sep;4(3):470-4.

  2010年度

  1. Fujita K, Kim YH, Yoshino M, Ichikawa M, Mio T, Mishima M. Acute Budd–Chiari syndrome caused by tumor thrombus of the inferior vena cava secondary to non-small cell lung cancer. Respiratory Medicine CME. 3: 26-8, 2010
  2. Kim YH, Yoh K, Niho S, Goto K, Ohmatsu H, Kubota K, Nishiwaki Y. Trends in chemotherapy for elderly patients with advanced non-small-cell lung cancer.　 Respir Med. 104;434-9, 2010
  3. Nagano T, Kim YH, Goto K, Kubota K, Ohmatsu H, Niho S, Yoh K, Naito Y, Saijo N, Nishiwaki Y. Re-challenge chemotherapy for relapsed non-small-cell lung cancer. Lung Cancer. 69(3):315-8, 2010
  4. Togashi Y, Masago K, Fukudo M, Terada T, Ikemi Y, Kim YH, Fujita S, Irisa K, Sakamori Y, Mio T, Inui K, Mishima M. Pharmacokinetics of Erlotinib and Its Active Metabolite OSI-420 in Patients with Non-small Cell Lung Cancer and Chronic Renal Failure Who Are Undergoing Hemodialysis. J Thorac Oncol. 5(5):601-5, 2010
  5. Togashi Y, Masago K, Fukudo M, Terada T, Fujita S, Irisa K, Sakamori Y, Kim YH, Mio T, Inui K, Mishima M. Cerebrospinal Fluid Concentration of Erlotinib and its Active Metabolite OSI-420 in Patients with Central Nervous System Metastases of Non-small Cell Lung Cancer. J Thorac Oncol. 5(7):950-5, 2010
  6. Kim YH, Mishima M, Miyagawa-Hayashino A. Treatment of pulmonary epithelioid hemangioendothelioma with bevacizumab. J Thorac Oncol. 5(7):1107-8, 2010
  7. Kim YH, Masago K, Mishima M. Erlotinib and gastrointestinal ulcer. J Thorac Oncol. 5(7):1108-9, 2010
  8. Kim YH, Mishima M, Yoshizawa A. Gemcitabine-induced acute eosinophilic pneumonia. J Thorac Oncol.5(8):1308-9, 2010
  9. Kim YH, Mio T, Masago K, Irisa K, Sakamori Y, Mishima M. Retrospective analysis of Japanese patients with relapse or refractory small-cell lung cancer treated with amrubicin hydrochloride . Oncology Letters. 1: 569-572, 2010
  10. Kim YH, Mio T, Hamamoto Y, Mishima M. Successful treatment with carboplatin and etoposide in a small-cell lung cancer patient undergoing hemodialysis. Respiratory Medicine CME. 3: 68–70, 2010
  11. Masago K, Togashi Y, Fukudo M, Terada T, Irisa K, Sakamori Y, Fujita S, Kim YH, Mio T, Inui KI, Mishima M. Good Clinical Response to Erlotinib in a Non-Small Cell Lung Cancer Patient Harboring Multiple Brain Metastases and a Double Active Somatic Epidermal Growth Factor Gene Mutation. Case Rep Oncol. 3(2):98-105, 2010
  12. Togashi Y, Kim YH, Miyahara R, Irisa K, Sakamori Y, Masago K, Mio T, Date H, Mishima M.　Octreotide, a somatostatin analogue, in the treatment of chylothorax associated with idiopathic fibrosing mediastinitis.　Tohoku J Exp Med. 222(1):51-3, 2010
  13. Fukuhara A, Masago K, Neo M, Fujibayashi S, Fujita S, Hatachi Y, Irisa K, Sakamori Y, Togashi Y, Kim YH, Mio T, Mishima M. Outcome of Surgical Treatment for Metastatic Vertebra Bone Tumor in Advanced Lung Cancer. Case Rep Oncol. 24;3(1):63-71, 2010
  14. Masago K, Fujita S, Irisa K, Kim YH, Ichikawa M, Mio T, Mishima M. Good clinical response to gefitinib in a non-small cell lung cancer patient harboring a rare somatic epidermal growth factor gene point mutation; codon 768 AGC > ATC in exon 20 (S768I). Jpn J Clin Oncol. 40(11):1105-9, 2010
  15. Masago K, A Fukuhara, Ito Y, Hatachi Y, Irisa K, Sakamori Y, Togashi Y, Fujita S, Kim YH, Mio T, Mishima M.　Infectious background of febrile advanced lung cancer patients who received chemotherapy. Oncology Letters. 1: 849-53, 2010
  16. Masago K, Fujita S, Togashi Y, Kim YH, Hatachi Y, Fukuhara A, Nagai H, Irisa K, Sakamori Y, Okuda C, Mio T, Mishima M. Clinical significance of pretreatment C-reactive protein in patients with advanced non-squamous, non-small cell lung cancer who received gefitinib. Oncology. 79(5-6):355-362, 2010
  17. Irisa K, Masago K, Togashi Y, Fujita S, Hatachi Y, Fukuhara A, Sakamori Y, Kim YH, Mio T, Mishima M.　Significance of pretreatment comorbidities in elderly patients with advanced non-small-cell lung cancer treated with chemotherapy or epidermal growth factor receptor-tyrosine kinase inhibitor. Med Oncol. 2010 Dec 7.
  18. Fujita S, Masago K, Hatachi Y, Fukuhara A, Hata A, Kaji R, Kim YH, Mio T, Mishima M, Katakami N. Genetic polymorphisms in the endothelial nitric oxide synthase gene correlate with overall survival in advanced non-small-cell lung cancer patients treated with platinum-based doublet chemotherapy. BMC Med Genet. 2010 Nov 30;11:167.

  2009年度

• Masago K, Fujita S, Kim YH, Hatachi Y, Fukuhara A, Nagai H, Irisa K, Ichikawa M, Mio T, Mishima M.　Effect of vascular endothelial growth factor polymorphisms on survival in advanced-stage non-small-cell lung cancer.　Cancer Sci.　100(10):1917-22, 2009
• Kim YH, Mio T, Mishima M. Gefitinib for non-small cell lung cancer patients with liver cirrhosis.　Intern Med. 48(18):1677-9, 2009
• Kim YH, Kubota K, Goto K, Yoh K, Niho S, Ohmatsu H, Saijo N, Nishiwaki Y. A phase I study of gemcitabine and carboplatin in patients with advanced non-small cell lung cancer and a performance status of 2. Jpn J Clin Oncol. 39(9):576-81, 2009
• Kim YH, Ishii G, Goto K, Ota S, Kubota K, Murata Y, Mishima M, Saijo N, Nishiwaki Y, Ochiai A. Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer.　 Lung Cancer. 65(1):105-11, 2009
• Ota S, Ishii G, Goto K, Kubota K, Kim YH, Kojika M, Murata Y, Yamazaki M, Nishiwaki Y, Eguchi K, Ochiai A. Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy.　Lung Cancer. 64(1):98-104, 2009
• Masago K, Fujita S, Kim YH, Ichikawa M, Hatachi Y, Fukuhara A, Nagai H, Irisa K, Mio T, Mishima M. Epidermal growth factor receptor (EGFR) double-activating somatic mutations in exons 19 and 21 in Japanese non-small cell lung cancer patients. Cancer Genet Cytogenet. 195(2):179-82, 2009